Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease

Journal of the Neurological Sciences

Volumn 314, Issue 1-2, 2012, Pages 41-47

  Bach, Jan Philipp ^a   Riedel, Oliver ^b   Klotsche, Jens ^b   Spottke, Annika ^c   Dodel, Richard ^a   Wittchen, Hans Ulrich ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Comorbidities; Dementia; Depression; EQ 5D; Neuropsychiatric symptoms; PD treatment costs

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; APOMORPHINE; BENZODIAZEPINE; BUDIPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; NOOTROPIC AGENT; RASAGILINE; SELEGILINE;

AGE DISTRIBUTION; AGED; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; GINKGO BILOBA; HALLUCINATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIST; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; COMORBIDITY; COST OF ILLNESS; DEMENTIA; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 84857064376     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.11.002     Document Type: Article

References (39)

1. S. von Campenhausen, B. Bornschein, R. Wick, K. Bötzel, C. Sampaio, and W. Poewe Prevalence and incidence of Parkinson's disease in Europe Eur. J. Neuropsychopharmacol. 15 2005 473 490
2. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, and K. Kieburtz Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 5 2007 384 386
3. K.K. Martikainen, T.H. Luukkaala, and R.J. Marttila Parkinson's disease and working capacity Mov Disord 21 12 2006 2187 2191
4. A. Schrag, and P. Banks Time of loss of employment in Parkinson's disease Mov Disord 21 11 2006 1839 1843
5. C.G. Goetz, and G.T. Stebbins Risk factors for nursing home placement in advanced Parkinson's disease Neurology 43 11 1993 2227 2229
6. S. von Campenhausen, Y. Winter, A. Rodrigues e Silva, C. Sampaio, E. Ruzicka, and P. Barone Cost of ilness and care in Parkinson's disease: An evaluation in six countries European Neuropsychopharmacology 21 2 2011 180 191
7. R. Ehret, M. Balzer-Geldsetzer, J.P. Reese, I. Dodel, E. Becker, and A. Christopher Direct costs for Parkinson's treatment in private neurology practices in Berlin Nervenarzt 80 4 2009 452 458
8. G. Wang, Q. Cheng, R. Zheng, Y.-Y. Tan, X.-K. Sun, and H.-Y. Zhou Economic burden or Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China Mov Disord 21 9 2006 1439 1443
9. S. Keller, T. Kessler, T. Meuser, D. Bremen, and W.H. Jost Analyse der direkten Kosten in der Parkinson-Therapie Nervenarzt 74 2003 1105 1109
10. A. Schrag Quality of life and depression in Parkinson's disease J Neurol Sci 248 1-2 2006 151 157
11. O. Riedel, I. Heuser, J. Klotsche, R. Dodel, and H.U. Wittchen Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD study J Geriatr Psychiatry Neurol 23 1 2010 27 34
12. O. Riedel, J. Klotsche, A. Spottke, G. Deuschl, H. Forstl, and F. Henn Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD) J Neurol 255 2 2008 255 264
13. D.J. Gelb, E. Oliver, and S. Gilman Diagnostic criteria for Parkinson disease Arch Neurol 56 1 1999 33 39
14. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 3 1992 181 184
15. O. Riedel, J. Klotsche, A. Spottke, G. Deuschl, H. Forstl, and F. Henn Frequency of dementia, depression, and other neuropsychiatric symptoms in 1449 outpatients with Parkinson's disease J Neurol 257 7 2010 1073 1082
16. M. Hoehn, and M. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
17. S. Fahn Unified Parkinson's disease rating scale S. Fahn, D. Calne, Recent developments in Parkinson's disease 1987 MacMillan Healthcare Information Florham Park, NJ 153 163
18. M. Folstein, S. Folstein, and P. McHugh Mini-mental state: a practical method for grading the mental state of patients by the clinician J Psychiatr Res 12 1975 189 198
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Text revision. 4 ed. Washington, DC: American Psychiatric Association 2000
20. M. Zaudig, W. Hiller, B. Geiselmann, E. Hansert, G. Linder, and W. Mombour SIDAM-Strukturiertes Interview für die Diagnose einer Demenz vom Alzheimer Typ, der Multiinfarkt- (oder vaskulären) Demenz und Demnzen anderer Ätiologien nach DSM-III-R, DSM-IV und ICD-10 1996 Hogrefe Göttingen
21. S. Montgomery, and M. Asberg A new depression scale, designed to be sensitive to change Br J Psychiatry 134 1979 382 389
22. EuroQuol Group EuroQuol: a new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
23. Bundesverband der pharmazeutischen Industrie. Rote Liste. Weinheim: Rote Liste Verlag 2009.
24. J.A. Barber, and S.G. Thompson Analysis of cost data in randomized trials: an application of the non-parametric bootstrap Stat Med 19 23 2000 3219 3236
25. A. Desgagne, A.M. Castilloux, J.F. Angers, and J. LeLorier The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data Pharmacoeconomics 13 5 1998 487 497
26. W. Greiner, T. Weijnen, M. Nieuwenhuizen, S. Oppe, X. Badia, and J. Busschbach A single European currency for EQ-5D health states. Results from a six-country study Eur J Health Econ 4 3 2003 222 231
27. I. Dengler, N. Leukel, T. Meuser, and W.H. Jost Prospective study of the direct and indirect costs of idiopathic Parkinson's disease Nervenarzt 77 10 2006 1204 1209
28. P. Lindgren, S. Campenhausen, A. Spottke, U. Siebert, and R. Dodel Cost of Parkinson's disease in Europe Eur J Neurol 12 Suppl. 1 2005 68 73
29. R.C. Dodel, M. Singer, R. Kohne-Volland, T. Szucs, B. Rathay, and E. Scholz The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis Pharmacoeconomics 14 3 1998 299 312
30. J. Möller, Y. Körner, R. Dodel, C. Meinsdorfner, K. Stiasny-Kolster, and A. Spottke Pharmacotherapy of Parkinson's disease in Germany J Neurol 252 2005 926 935
31. D.A. Gallagher, and A. Schrag Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease CNS Drugs 22 7 2008 563 586
32. F. Stocchi, O. Rascol, K. Kieburtz, W. Poewe, J. Jankovic, and E. Tolosa Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study Ann Neurol 68 1 2010 18 27
33. K.M. Eggert, W.H. Oertel, H. Reichmann, G. Arnold, H. Baas, and D. Berg Parkinson-Syndrome: Diagnostik und Therapie H. Diener, N. Putzki, Leitlinien für die Diagnostik und Therapie in der Neurologie 2008 Georg Thieme Verlag Stuttgart
34. A. Storch, G. Ebersbach, G. Fuchs, W.H. Jost, P. Odin, and G. Reifschneider Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis Fortschr Neurol Psychiatr 76 12 2008 715 724
35. L.M. Shulman, R.L. Taback, A.A. Rabinstein, and W.J. Weiner Non-recognition of depression and other non-motor symptoms in Parkinson's disease Parkinsonism Relat Disord 8 3 2002 193 197
36. D. Weintraub, K.H. Morales, P.J. Moberg, W.B. Bilker, C. Balderston, and J.E. Duda Antidepressant studies in Parkinson's disease: a review and meta-analysis Mov Disord 20 9 2005 1161 1169
37. W. Poewe, S. Gauthier, D. Aarsland, J.B. Leverenz, P. Barone, and D. Weintraub Diagnosis and management of Parkinson's disease dementia Int J Clin Pract 62 10 2008 1581 1587
38. G. Deuschl, and W. Maier S3 guideline dementia [cited 2011 14.04]; Available from www.dgn.org/images/stories/dgn/leitlinien/ll-demenz/ll-demenz- lang-170210.pdf 2008
39. J.P. Bach, U. Ziegler, G. Deuschl, R. Dodel, and G. Doblhammer-Reiter Projected numbers of people with movement disorders in the years 2030 and 2050 Mov Disord 26 12 2011 2286 2290